Cangene given biodefense contract for anthrax antibody
The contract is for the U.S. Department of Health and Human Services biodefense program, which is stockpiling various vaccines and remedies for biological and chemical substances, including anthrax. Cangene will provide its AIGIV, a hyperimmune antibody product that is used to combat the Bacillus anthracis bacteria.
"We are proud to have been selected by the U.S. government for this important medical countermeasure," John A. Sedor, the president and CEO of Cangene, said. "This marks our second major biodefense contract this year, with the extension of our VIGIV contract with the Centers for Disease Control and Prevention that we announced earlier this month, underscoring our leadership in biodefense. We appreciate our long-standing relationship with the U.S. Department of Health and Human Services, and look forward to continuing to support its critical biodefense preparedness program."
The five-year contract, for the collection and storage of anti-anthrax human plasma sufficient to manufacture 10,000 doses of bulk drug substance, is for the first task and delivery of AIGIV. The order is estimated to be worth, at its maximum potential, approximately $264 million.
Cangene Corp. is located in Winnipeg, Canada, and is one of Canada's oldest and largest biopharmaceutical companies. Its focus is on specialty therapeutics, like the anthrax antibody being provided in the contact.